{"transactions":[{"id":867103,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":10505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":10505,"derivative":{"exercise_price":13.78,"expiration_date":"2036-02-29","underlying":"Common Stock","underlying_shares":10505},"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":867102,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":607,"price":13.78,"value":8364.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person."}],"balance_after":93864,"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":867101,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:16:13.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":7353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":94471,"source":{"system":"sec-edgar","filing":"0001193125-26-088241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526088241/ownership.xml","form_type":"4"}},{"id":944471,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T21:03:52.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":9515,"price":9.21,"value":87633.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025."}],"balance_after":87118,"source":{"system":"sec-edgar","filing":"0001193125-26-006278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526006278/ownership.xml","form_type":"4"}},{"id":1092346,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:11:49.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":1022,"price":9.82,"value":10036.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 1,022 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":95369,"source":{"system":"sec-edgar","filing":"0000950170-25-093852","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025093852/ownership.xml","form_type":"4"}},{"id":1228401,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":45714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2025 with respect to shares of Common Stock, with 33% vesting on January 1, 2026 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":45714,"derivative":{"exercise_price":10.09,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":45714},"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1228400,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-04","kind":"sale","planned":false,"acquired":false,"shares":679,"price":8.99,"value":6104.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":95369,"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1228399,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:43:16.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":96048,"source":{"system":"sec-edgar","filing":"0000950170-25-032263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025032263/ownership.xml","form_type":"4"}},{"id":1310649,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:16:47.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":7422,"price":12.18,"value":90399.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2025, and does not represent a volitional trade by the Reporting Person."}],"balance_after":64048,"source":{"system":"sec-edgar","filing":"0000950170-25-002115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025002115/ownership.xml","form_type":"4"}},{"id":1310648,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-06T21:16:47.000Z","date":"2025-01-02","kind":"sale","planned":false,"acquired":false,"shares":556,"price":12.03,"value":6688.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 556 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":71470,"source":{"system":"sec-edgar","filing":"0000950170-25-002115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017025002115/ownership.xml","form_type":"4"}},{"id":1459950,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-07-03T17:15:04.000Z","date":"2024-07-01","kind":"sale","planned":false,"acquired":false,"shares":405,"price":22.93,"value":9286.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 405 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 28, 2024."}],"balance_after":71470,"source":{"system":"sec-edgar","filing":"0000950170-24-081259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024081259/ownership.xml","form_type":"4"}},{"id":1596205,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-05T21:10:16.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":45072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 1, 2024 with respect to shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":45072,"derivative":{"exercise_price":32.66,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":45072},"source":{"system":"sec-edgar","filing":"0000950170-24-025902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025902/ownership.xml","form_type":"4"}},{"id":1596204,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:10:16.000Z","date":"2024-03-04","kind":"sale","planned":false,"acquired":false,"shares":605,"price":32.99,"value":19958.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":71470,"source":{"system":"sec-edgar","filing":"0000950170-24-025902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025902/ownership.xml","form_type":"4"}},{"id":1596203,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-05T21:10:16.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":31230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":72075,"source":{"system":"sec-edgar","filing":"0000950170-24-025902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024025902/ownership.xml","form_type":"4"}},{"id":1685479,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T21:44:43.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":4301,"price":29.46,"value":126707.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a mandatory \"sell-to-cover\" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2024, and does not represent a volitional trade by the Reporting Person."}],"balance_after":40845,"source":{"system":"sec-edgar","filing":"0000950170-24-002502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024002502/ownership.xml","form_type":"4"}},{"id":1685478,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-01-05T21:44:43.000Z","date":"2024-01-03","kind":"sale","planned":false,"acquired":false,"shares":307,"price":30.12,"value":9246.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 307 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2023."}],"balance_after":45146,"source":{"system":"sec-edgar","filing":"0000950170-24-002502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024002502/ownership.xml","form_type":"4"}},{"id":1833840,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-07-06T19:34:22.000Z","date":"2023-07-03","kind":"sale","planned":false,"acquired":false,"shares":360,"price":40.51,"value":14583.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 360 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.52, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price."}],"balance_after":45146,"source":{"system":"sec-edgar","filing":"0001209191-23-041495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123041495/doc4.xml","form_type":"4"}},{"id":1846506,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T21:52:19.000Z","date":"2023-06-20","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 64,062 shares as of June 20, 2023."}],"balance_after":57750,"derivative":{"exercise_price":12.27,"expiration_date":"2030-02-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-23-039148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123039148/doc4.xml","form_type":"4"}},{"id":1846505,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-06-22T21:52:19.000Z","date":"2023-06-20","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":45,"value":225000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 5,000 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 21, 2023."}],"balance_after":45146,"source":{"system":"sec-edgar","filing":"0001209191-23-039148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123039148/doc4.xml","form_type":"4"}},{"id":1846504,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-06-22T21:52:19.000Z","date":"2023-06-20","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":12.27,"value":61350.0,"ownership":{"direct":true},"balance_after":50146,"source":{"system":"sec-edgar","filing":"0001209191-23-039148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123039148/doc4.xml","form_type":"4"}},{"id":1973476,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-03T22:12:34.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":34674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2023 with respect to shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":34674,"derivative":{"exercise_price":40.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":34674},"source":{"system":"sec-edgar","filing":"0001209191-23-015732","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015732/doc4.xml","form_type":"4"}},{"id":1973475,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T22:12:34.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":6134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":45146,"source":{"system":"sec-edgar","filing":"0001209191-23-015732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015732/doc4.xml","form_type":"4"}},{"id":1973474,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T22:12:34.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":24539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":39012,"source":{"system":"sec-edgar","filing":"0001209191-23-015732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123015732/doc4.xml","form_type":"4"}},{"id":2060422,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:21:01.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":1692,"price":37.21,"value":62959.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023."}],"balance_after":14473,"source":{"system":"sec-edgar","filing":"0001209191-23-002412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123002412/doc4.xml","form_type":"4"}},{"id":2060421,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:21:01.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":231,"price":34.48,"value":7964.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Sale of 231 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2022."}],"balance_after":16165,"source":{"system":"sec-edgar","filing":"0001209191-23-002412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123002412/doc4.xml","form_type":"4"}},{"id":2060420,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-06T22:21:01.000Z","date":"2022-07-01","kind":"sale","acquired":false,"shares":105,"price":51.74,"value":5432.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of 105 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022."}],"balance_after":16165,"source":{"system":"sec-edgar","filing":"0001209191-23-002412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919123002412/doc4.xml","form_type":"4"}},{"id":2347825,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-08T00:19:45.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":15395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter."}],"balance_after":15395,"derivative":{"exercise_price":79.85,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":15395},"source":{"system":"sec-edgar","filing":"0001209191-22-016851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016851/doc4.xml","form_type":"4"}},{"id":2347824,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":63305,"kind":"person","name":"Clark Eliana","position":1,"cik":"0001914448","reported_name":"Clark Eliana","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-08T00:19:45.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":10527,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit."}],"balance_after":16165,"source":{"system":"sec-edgar","filing":"0001209191-22-016851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919122016851/doc4.xml","form_type":"4"}}]}